Abstract | OBJECTIVE: DESIGN: Phase II clinical trial. SETTING: Community dwelling men making visits to physician offices. PATIENT(S): INTERVENTION(S): MAIN OUTCOME MEASURE(S): RESULT(S): CONCLUSION(S):
Enclomiphene citrate reverses the two hallmarks of secondary hypogonadism, namely, low serum total T and low or inappropriately normal LH while preserving sperm production. CLINICAL TRIAL REGISTRATION NUMBER: NCT01270841 (ClinicalTrials.gov Identifier NCT01270841).
|
Authors | Ronald D Wiehle, Gregory K Fontenot, Jenny Wike, Kuang Hsu, Jennifer Nydell, Larry Lipshultz, ZA-203 Clinical Study Group |
Journal | Fertility and sterility
(Fertil Steril)
Vol. 102
Issue 3
Pg. 720-7
(Sep 2014)
ISSN: 1556-5653 [Electronic] United States |
PMID | 25044085
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2014 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Sex Hormone-Binding Globulin
- Testosterone
- Estradiol
- boldenone
- Luteinizing Hormone
- Enclomiphene
|
Topics |
- Administration, Oral
- Administration, Topical
- Adult
- Enclomiphene
(therapeutic use)
- Estradiol
(blood)
- Humans
- Hypogonadism
(drug therapy)
- Luteinizing Hormone
(blood)
- Male
- Middle Aged
- Oligospermia
(blood, prevention & control)
- Sex Hormone-Binding Globulin
(analysis)
- Testosterone
(administration & dosage, analogs & derivatives, blood)
- Up-Regulation
(drug effects)
|